Author:
Hammami Muhammad Bader,Al-Taee Ahmad,Meeks Marshall,Fesler Mark,Hurley M Yadira,Cao Dengfeng,Lai Jin-Ping
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference13 articles.
1. Madanat YF, Smith MR, Almasan A, et al. Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. Blood Lymphat Cancer. 2016;6:1–6.
2. O’Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126(25):2686–94.
3. Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123(22):3398–405.
4. Villanacci V, Manenti S, Antonelli E, et al. Non-IBD colitides: clinically useful histopathological clues. Rev Esp Enferm Dig. 2011;103(7):366–72.
5. Lee FD. Drug-related pathological lesions of the intestinal tract. Histopathology. 1994;25(4):303–8.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献